REDMOND, Wash., Jan. 29 /PRNewswire/ -- Healionics Corporation, a
provider of tissue regeneration and device biointegration solutions to
healthcare manufacturers, today announced that it has raised $1.7 million
in a Series A financing. The financing was led by individual investors
including Carl Lombardi, former CEO of SpaceLabs Medical and Sam Naficy,
M.D., Medical Director of Naficy Plastic Surgery & Rejuvenation Center.
"We are pleased to secure this financing, which provides recognition of
our technology platform and allows Healionics to continue expanding the
potential of STAR materials to enhance current and next generation medical
devices," said Rob Brown, Chief Executive Officer of Healionics. "These
funds will be used specifically to scale up the STAR material manufacturing
process, to expand and accelerate preclinical studies of STAR materials and
to advance our business development activities."
Healionics' propriety STAR Material -- Sphere Templated Angiogenic
Regenerative Material -- is specifically engineered to enhance
biointegration and promote healing. Described as the 'Gore-Tex(TM) of
biomaterials,' STAR is designed to enable the biocompatibility of a wide
range of medical devices that are implanted into the body.
"Healionics has a very promising technology that offers widespread
opportunities in a rapidly expanding cosmetic market," said Sam Naficy,
M.D. "It is this versatility and expansiveness that make Healionics a very
attractive business model, and I look forward to the future advancement of
this Company."
Healionics was formed in March 2007. To date, Healionics has entered
into multiple agreements for the advancement of its STAR(TM) material into
various market applications including diabetes, wound care and infusion
therapy.
About Healionics Corporation
Healionics is a privately held biomaterials company whose mission is to
be the leading partner of tissue regeneration and device biointegration
solutions to healthcare manufacturers. Healionics has licensed STAR
Material -- Sphere Templated Angiogenic Regenerative Material -- that works
with the body to promote healing and enables the biocompatibility of a wide
range of medical devices that are implanted into the body. Healionics was
voted the Best Technology Investment Opportunity at the Zino Society's 2007
Zillionaire Investment Forum and was recently named "Most Promising New
Biotech Firm of 2007" by Seattle Business Monthly. Healionics will debut
its technology as an exhibitor (booth #790) at the Medical Design &
Manufacturing West (MD&M West) 2008 conference, Jan. 29-31 in Anaheim,
Calif. Healionics Corporation is headquartered in Redmond, Washington. For
more information, please visit http://www.healionics.com.
Contact:
Julie Rathbun
Rathbun Communications, Inc.
(206) 769-9219
Julie@rathbuncomm.com
SOURCE Healionics Corporation
 back to top
Related links:
http://www.healionics.com
CONTACT:
Julie Rathbun of Rathbun Communications,
Inc., +1-206-769-9219, Julie@rathbuncomm.com, for Healionics
Corporation
|
